| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 2077962 | Cell Stem Cell | 2011 | 5 Pages |
Abstract
Stock market volatility in the cell therapy industry has greatly hindered the investment necessary to fund translational therapies. Here, we review the volatility of leading companies and suggest that a distinct industry is maturing to a point at which the volatility should subside, providing a more attractive environment for future growth.
Related Topics
Life Sciences
Biochemistry, Genetics and Molecular Biology
Biotechnology
Authors
David A. Brindley, Brock C. Reeve, William A. Sahlman, Greg A. Bonfiglio, Natasha L. Davie, Emily J. Culme-Seymour, Chris Mason,